Market Overview:
The global lung cancer diagnosis and therapeutics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of lung cancer, rising awareness about early diagnosis and treatment options, and technological advancements in the field of diagnostics and therapeutics. The global lung cancer diagnosis and therapeutics market is segmented on the basis of type into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is more common than SCLC, accounting for approximately 85% of all cases diagnosed worldwide. On the basis of application, the market is segmented into hospitals and cancer research centers. Geographically, it is segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . North America dominates the global Lung Cancer Diagnosis And Therapeutics Market due to high prevalence rateof Lung Cancer in this region followed by Europe .
Product Definition:
Lung cancer is a type of cancer that starts in the lungs. The most common type of lung cancer is called non-small cell lung cancer. Small cell lung cancer is a less common type of lung cancer.
Non-Small Cell Lung Cancer:
Non-small cell lung cancer (NSCLC) is one of the histological types of lung cancer. It accounts for a significant percentage of all lung cancers and causes more than 85% cases of advanced stage Lung Cancer in the U.S. According to estimates from the American Cancer Society, there are about 228,30o NSCLC cases in 2018 and it is expected to rise up till 240,00o by 2023 globally.
Small Cell Lung Cancer:
Small cell lung cancer (SCLC) is one of the most common types of lung cancer. It accounts for 10-15% of all lung cancers and 30-40% of non-small cell lung cancers. The disease has a poor prognosis with a survival rate below 1 year. SCLC usually presents as an interstitial pneumonia, which may or may not be clinically apparent at the time of diagnosis.
Application Insights:
The market is segmented by application into hospitals, oncology centers and others. Hospitals held the largest share in 2017 owing to availability of advanced healthcare facilities and a large number of diagnosed patients that necessitates an increased number of treatment centers. The presence of various research studies supporting the use of immunotherapy for lung cancer diagnosis further supports segment growth.
Oncology centers are anticipated to witness lucrative growth over the forecast period due to increasing incidence rates coupled with rising awareness about available treatment options such as chemotherapy, radiation therapy and hormonal therapy among other therapies such as surgery, which aids in tumor removal from body cavities or organs without affecting their functions. These factors are expected to increase demand for lung cancer diagnosis & therapeutics during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; in this region. The companies are engaged in extensive R&D activities for lung cancer diagnosis and therapies. For instance, Pfizer is working on a new diagnostic test for lung cancer that will provide results within 15 minutes instead of the current 24 hours required by other tests. Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing awareness about early diagnosis among patients coupled with rising disposable income levels of consumers especially in China and India which makes it easier for them to opt for expensive treatment options rather than opting for palliative care services leading to an increase in demand over forecast period (2018-2030).
Growth Factors:
- Increasing incidence of lung cancer
- Growing awareness about lung cancer and its early detection methods
- Rising demand for better and more effective treatment options for lung cancer patients
- Technological advancements in the field of diagnostics and therapeutics for lung cancer
- Increasing funding for research on lung cancer diagnosis and therapeutics
Scope Of The Report
Report Attributes
Report Details
Report Title
Lung Cancer Diagnosis and Therapeutics Market Research Report
By Type
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
By Application
Hospitals, Cancer Research Centers
By Companies
AstraZeneca, Eli Lilly, Sanofi, ArQule, Daiichi Sankyo, Celgene, Merck, Pfizer, Boehringer Ingelheim, Roche, Genentech, GSK, Pharmacyclics, Novartis, Bayer, Bristol-Myers Squibb, Eisai, AbbVie
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
209
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Lung Cancer Diagnosis and Therapeutics Market Report Segments:
The global Lung Cancer Diagnosis and Therapeutics market is segmented on the basis of:
Types
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Cancer Research Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Eli Lilly
- Sanofi
- ArQule
- Daiichi Sankyo
- Celgene
- Merck
- Pfizer
- Boehringer Ingelheim
- Roche
- Genentech
- GSK
- Pharmacyclics
- Novartis
- Bayer
- Bristol-Myers Squibb
- Eisai
- AbbVie
Highlights of The Lung Cancer Diagnosis and Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- By Application:
- Hospitals
- Cancer Research Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lung Cancer Diagnosis and Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lung cancer is a type of cancer that begins in the lungs. The cause of lung cancer is not known, but it can be caused by smoking, exposure to asbestos, or other factors. Lung cancer usually grows slowly and may not be noticed until it has advanced far enough to cause serious health problems. Treatment for lung cancer depends on the stage of the disease and may include surgery, chemotherapy, radiation therapy, or a combination of treatments.
Some of the major players in the lung cancer diagnosis and therapeutics market are AstraZeneca, Eli Lilly, Sanofi, ArQule, Daiichi Sankyo, Celgene, Merck, Pfizer, Boehringer Ingelheim, Roche, Genentech, GSK, Pharmacyclics, Novartis, Bayer, Bristol-Myers Squibb, Eisai, AbbVie.
The lung cancer diagnosis and therapeutics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lung Cancer Diagnosis and Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lung Cancer Diagnosis and Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lung Cancer Diagnosis and Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lung Cancer Diagnosis and Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lung Cancer Diagnosis and Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Lung Cancer Diagnosis and Therapeutics Market Size and Y-o-Y Growth
4.5.2 Lung Cancer Diagnosis and Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Non-Small Cell Lung Cancer
5.2.2 Small Cell Lung Cancer
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Cancer Research Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lung Cancer Diagnosis and Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lung Cancer Diagnosis and Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Non-Small Cell Lung Cancer
9.6.2 Small Cell Lung Cancer
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Cancer Research Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Non-Small Cell Lung Cancer
10.6.2 Small Cell Lung Cancer
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Cancer Research Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Non-Small Cell Lung Cancer
11.6.2 Small Cell Lung Cancer
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Cancer Research Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Non-Small Cell Lung Cancer
12.6.2 Small Cell Lung Cancer
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Cancer Research Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Non-Small Cell Lung Cancer
13.6.2 Small Cell Lung Cancer
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Cancer Research Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lung Cancer Diagnosis and Therapeutics Market: Competitive Dashboard
14.2 Global Lung Cancer Diagnosis and Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Eli Lilly
14.3.3 Sanofi
14.3.4 ArQule
14.3.5 Daiichi Sankyo
14.3.6 Celgene
14.3.7 Merck
14.3.8 Pfizer
14.3.9 Boehringer Ingelheim
14.3.10 Roche
14.3.11 Genentech
14.3.12 GSK
14.3.13 Pharmacyclics
14.3.14 Novartis
14.3.15 Bayer
14.3.16 Bristol-Myers Squibb
14.3.17 Eisai
14.3.18 AbbVie
